Yachnin, Jeffrey

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 406

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., et al. (2019) · The Lancet Oncology

Monoclonal and Polyclonal Antibodies ResearchLung Cancer Treatments and Mutations

Cited by 237